ADMA Earnings & Financial Statements
ADMA Biologics, Inc.
$10.74
+$0.40(+3.87%)
63
Overall
70
Value
54
Tech
65
Quality
Market Cap
$2.32B
Volume
764.64K
52W Range
$7.21 - $20.46
Target Price
$15.80
ADMA earnings and financial statements: ADMA Biologics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ADMA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $510.17M | $426.45M | $258.21M | $154.08M | $80.94M |
| Cost of revenue | $217.41M | $206.90M | $169.27M | $118.81M | $79.77M |
| Operating income | $191.44M | $138.98M | $21.63M | -$39.37M | -$58.37M |
| EBITDA | $198.58M | $148.64M | $6.95M | -$39.03M | -$53.09M |
| Net income | $146.93M | $197.67M | -$28.24M | -$65.90M | -$71.65M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $624.24M | $488.68M | $329.18M | $348.46M | $276.22M |
| Total liabilities | $146.92M | $139.66M | $193.98M | $196.49M | $135.08M |
| Shareholders’ equity | $477.32M | $349.02M | $135.21M | $151.97M | $141.17M |
| Cash and equivalents | $87.63M | $103.15M | $51.35M | $86.52M | $51.09M |
| Long-term debt | $75.98M | $80.90M | $140.37M | $153.54M | $102.33M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $50.40M | $118.67M | $8.80M | -$59.51M | -$112.37M |
| Capital expenditure | -$22.89M | -$8.57M | -$4.98M | -$13.91M | -$13.51M |
| Free cash flow | $27.50M | $110.10M | $3.82M | -$73.42M | -$125.88M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ADMA | $10.74 | +3.9% | 764.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |